Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAGE-547 90 μg/kg/h · 1 trial · 1 indication
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group. |
| SAGE-547 90 μg/kg/h | EXPERIMENTAL | Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours). |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Intravenous infusion of matching placebo for SAGE-547. |
| SAGE-547 90 μg/kg/h | DRUG | Intravenous infusion of SAGE-547 |
Key Inclusion Criteria: * Participant either must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s). * Participant had a major depressive episode that began no earlier than the third tri...
SAGE-547 90 μg/kg/h is an investigational small molecule being developed for the treatment of postpartum depression. It is currently in Phase 3 clinical development and has been studied in a completed trial involving 108 female participants with moderate postpartum depression.
SAGE-547 90 μg/kg/h is being developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SUPN.
SAGE-547 90 μg/kg/h is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 3 trial has been completed, but the drug remains under clinical investigation.
SAGE-547 90 μg/kg/h has been studied in one completed Phase 3 trial, NCT02942017, titled 'A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C).' The trial enrolled 108 female participants in the United States.
SAGE-547 90 μg/kg/h is a specific dose of the investigational drug SAGE-547. The trial NCT02942017 evaluated this dose in participants with moderate postpartum depression. The drug is being developed by Supernus Pharmaceuticals, Inc.